Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078417 | 0.86 | CNR1 (0.57) | CNR1FAAHCNR2 | |
| SCHEMBL4079548 | 0.83 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL4079987 | 0.82 | CNR1 (0.57) | CNR1FAAHCNR2 | |
| SCHEMBL4089449 | 0.82 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL4087343 | 0.81 | CYP2C19 (0.41) | CNR1FAAHCNR2 | |
| SCHEMBL4084883 | 0.80 | HPGD (0.43) | CNR1NPC1RAB9AFAAH | |
| SCHEMBL4075655 | 0.79 | CNR1 (0.51) | CNR1FAAH | |
| SCHEMBL4075813 | 0.79 | CNR1 (0.46) | CNR1FAAHCNR2 | |
| SCHEMBL4075586 | 0.79 | NPC1 (0.44) | CNR1NPC1RAB9AFAAHEPHX1 | |
| SCHEMBL4075669 | 0.78 | FABP3 (0.44) | CNR1FAAHCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | claimed |
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | disclosed |
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | CNR1, CNR2, GPR119 | CNR1 1/4885NPC1 205/4885RAB9A 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.